FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3203822059> ?p ?o ?g. }

• W3203822059 endingPage "4908" @default.
• W3203822059 startingPage "4908" @default.
• W3203822059 abstract "To Evaluate the correlation between tumor dosimetric parameters with objective tumor response (OR) and overall survival (OS) in patients with surgically unresectable colorectal liver metastasis (CRLM) undergoing resin-based Ytrrium-90 selective internal radiation therapy (Y90 SIRT).45 consecutive patients with CRLM underwent resin-based Y90 SIRT in one or both hepatic lobes (66 treated lobes total). Dose volume histograms were created with MIM Sureplan® v.6.9 using post-treatment SPECT/CT. Dosimetry analyses were based on the cumulative volume of the five largest tumors in each treatment session and non-tumoral liver (NTL) dose. Receiver operating characteristic (ROC) curve was used to evaluate tumor dosimetric factors in predicting OR by Response Evaluation Criteria for Solid Tumors at 3 months post-Y90. Additionally, ROC curve was used to evaluate non-tumoral liver dose as a predictor of grade ≥ 3 liver toxicity and radioembolization induced liver disease (REILD) 3 months post Y90. To minimize for potential confounding demographic and clinical factors, univariate and multivariate analysis of survival with mean tumor dose as one of the factors were also performed. Kaplan-Meier estimation was used for OS analysis from initial Y90 SIRT.26 out of 45 patients had OR with a median OS of 17.2 months versus 6.8 months for patients without OR (p < 0.001). Mean tumor dose (TD) of the five largest tumors was the strongest predictor of OR with an area under the curve of 0.73 (p < 0.001). Minimum TD, and TD to 30%, 50%, and 70% of tumor volume also predicted OR (p's < 0.05). Mean TD ≥ 100 Gy predicted a significantly prolonged median OS of 19 vs. 11 months for those receiving TD < 100 Gy (p = 0.016). On univariate analysis, mean TD < 100 Gy, presence of any genomic mutation, presence of MAPK pathway mutation, bilobar hepatic metastases and diffuse metastatic disease (>10 lesions per liver lobe) were found to be predictors of shorter median OS. On multivariate analysis, mean TD < 100 Gy, presence of any genomic mutation, and diffuse hepatic metastatic disease were found to be independent predictors of shorter OS. Overall, six (13.3%) patients developed grade ≥ 3 liver toxicity post Y90 of whom two (4.4%) patients developed REILD. No dose threshold predicting grade ≥ 3 liver toxicity or REILD was identified.Mean TD ≥ 100 Gy in patients with unresectable CRLM undergoing resin-based Y90 SIRT predicts OR and prolonged OS." @default.
• W3203822059 created "2021-10-11" @default.
• W3203822059 creator A5006903084 @default.
• W3203822059 creator A5008540039 @default.
• W3203822059 creator A5010786422 @default.
• W3203822059 creator A5035096031 @default.
• W3203822059 creator A5040880164 @default.
• W3203822059 creator A5062465562 @default.
• W3203822059 creator A5063350289 @default.
• W3203822059 creator A5065441036 @default.
• W3203822059 creator A5076327694 @default.
• W3203822059 creator A5082589115 @default.
• W3203822059 date "2021-09-29" @default.
• W3203822059 modified "2023-10-17" @default.
• W3203822059 title "Role of Resin Microsphere Y90 Dosimetry in Predicting Objective Tumor Response, Survival and Treatment Related Toxicity in Surgically Unresectable Colorectal Liver Metastasis: A Retrospective Single Institution Study" @default.
• W3203822059 cites W1979522191 @default.
• W3203822059 cites W1986389253 @default.
• W3203822059 cites W1989002398 @default.
• W3203822059 cites W1996633016 @default.
• W3203822059 cites W2009808474 @default.
• W3203822059 cites W2032861970 @default.
• W3203822059 cites W2067116879 @default.
• W3203822059 cites W2071602611 @default.
• W3203822059 cites W2079586464 @default.
• W3203822059 cites W2083455565 @default.
• W3203822059 cites W2101815035 @default.
• W3203822059 cites W2103849118 @default.
• W3203822059 cites W2115774478 @default.
• W3203822059 cites W2139248078 @default.
• W3203822059 cites W2146613069 @default.
• W3203822059 cites W2155263737 @default.
• W3203822059 cites W2168313339 @default.
• W3203822059 cites W2284060732 @default.
• W3203822059 cites W2315387060 @default.
• W3203822059 cites W2415458991 @default.
• W3203822059 cites W2419345135 @default.
• W3203822059 cites W2469557469 @default.
• W3203822059 cites W2502245036 @default.
• W3203822059 cites W2548218639 @default.
• W3203822059 cites W2588199348 @default.
• W3203822059 cites W2592028230 @default.
• W3203822059 cites W2603497413 @default.
• W3203822059 cites W2620258448 @default.
• W3203822059 cites W2744084279 @default.
• W3203822059 cites W2800691104 @default.
• W3203822059 cites W2800875933 @default.
• W3203822059 cites W2884273160 @default.
• W3203822059 cites W2889739192 @default.
• W3203822059 cites W2909163269 @default.
• W3203822059 cites W2911352539 @default.
• W3203822059 cites W2996945400 @default.
• W3203822059 cites W3009963727 @default.
• W3203822059 cites W3023046633 @default.
• W3203822059 cites W3040084298 @default.
• W3203822059 cites W3089820999 @default.
• W3203822059 cites W3096906134 @default.
• W3203822059 cites W3118964091 @default.
• W3203822059 cites W3136043406 @default.
• W3203822059 doi "https://doi.org/10.3390/cancers13194908" @default.
• W3203822059 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8508412" @default.
• W3203822059 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34638392" @default.
• W3203822059 hasPublicationYear "2021" @default.
• W3203822059 type Work @default.
• W3203822059 sameAs 3203822059 @default.
• W3203822059 citedByCount "9" @default.
• W3203822059 countsByYear W32038220592022 @default.
• W3203822059 countsByYear W32038220592023 @default.
• W3203822059 crossrefType "journal-article" @default.
• W3203822059 hasAuthorship W3203822059A5006903084 @default.
• W3203822059 hasAuthorship W3203822059A5008540039 @default.
• W3203822059 hasAuthorship W3203822059A5010786422 @default.
• W3203822059 hasAuthorship W3203822059A5035096031 @default.
• W3203822059 hasAuthorship W3203822059A5040880164 @default.
• W3203822059 hasAuthorship W3203822059A5062465562 @default.
• W3203822059 hasAuthorship W3203822059A5063350289 @default.
• W3203822059 hasAuthorship W3203822059A5065441036 @default.
• W3203822059 hasAuthorship W3203822059A5076327694 @default.
• W3203822059 hasAuthorship W3203822059A5082589115 @default.
• W3203822059 hasBestOaLocation W32038220591 @default.
• W3203822059 hasConcept C121608353 @default.
• W3203822059 hasConcept C126322002 @default.
• W3203822059 hasConcept C126838900 @default.
• W3203822059 hasConcept C126894567 @default.
• W3203822059 hasConcept C143998085 @default.
• W3203822059 hasConcept C144301174 @default.
• W3203822059 hasConcept C2778019345 @default.
• W3203822059 hasConcept C2779013556 @default.
• W3203822059 hasConcept C2779185275 @default.
• W3203822059 hasConcept C29730261 @default.
• W3203822059 hasConcept C2989005 @default.
• W3203822059 hasConcept C38180746 @default.
• W3203822059 hasConcept C509974204 @default.
• W3203822059 hasConcept C526805850 @default.
• W3203822059 hasConcept C58471807 @default.
• W3203822059 hasConcept C71924100 @default.
• W3203822059 hasConcept C75088862 @default.
• W3203822059 hasConcept C90924648 @default.
• W3203822059 hasConceptScore W3203822059C121608353 @default.

• next